Spots Global Cancer Trial Database for Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)
Official Title: Open Label Study of ONTAK® (Denileukin Diftitox, DAB389IL-2) to Estimate Response in Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status
Study ID: NCT00211198
Conditions
Interventions
Study Description
Brief Summary: The purpose of this research study is to evaluate how effective ONTAK is in the treatment of cutaneous T-cell Lymphoma (CTCL) and determine whether the presence of a type of protein called CD25 on the cancer cells makes a difference in how the body responds to the treatment. The hypothesis is that there is no difference in response rate for patients whose tumor cells are CD25 positive or negative.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
City of Hope National Medical Center, Duarte, California, United States
Yale University School of Medicine, New Haven, Connecticut, United States
The University of Iowa, Iowa City, Iowa, United States
New England Medical Center, Boston, Massachusetts, United States
University Hospitals of Cleveland, Cleveland, Ohio, United States
Ohio State University, Columbus, Ohio, United States
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Vanderbilt University, Nashville, Tennessee, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Contact Details
Name: Francine Foss, M.D.
Affiliation: Yale University
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
